Data presented today supported the use of the Barostim neuromodulation device from CVRx (Nasdaq:CVRX) in patients with cardiovascular diseases. The BeAT-HF trial evaluated the Barostim extravascular, implantable neuromodulation device. Dr. Michael Zile, professor of cardiology at the Medical University of South Carolina, presented findings at the second annual Technology and Heart Failure (HF) Therapeutics (THT) […]
CVRx Inc.
CVRx nearly doubles its revenue in Q4
CVRx (NASDAQ: CVRX) reported Street-beating Q4 results amid increased adoption of its implantable neuromodulation system for treating heart failure symptoms. Minneapolis-based CVRx announced yesterday evening that it lost $10.5 million, or 51¢ per share, off of $7.2 million in revenue for the quarter that ended Dec. 31. 2022. Sales were up 96% compared with the […]
CVRx launches new Barostim programmer in U.S.
CVRx (Nasdaq:CVRX) announced that it launched its new Barostim programmer following its approval by the FDA earlier this year. Minneapolis-based CVRx designed its second-generation programmer to operate on an upgraded cellular network to enable remote view access. It also includes an improved user interface that simplifies implantable pulse generator (IPG) programming. According to a news […]
FDA approves magnetic resonance labeling for CVRx’s Barostim neuromodulation system
CVRx (Nasdaq:CVRX) announced today that the FDA approved magnetic resonance (MR) conditional labeling for its Barostim system. The Barostim neuromodulation system for treating the symptoms of heart failure now includes instructions to allow for safe MRI scans of the head and lower extremities, offering heart failure patients implanted with Barostim more diagnostic options. Minneapolis-based CVRx […]
CVRx rises on Street-beating Q3
CVRx (NSDQ:CVRX) shares ticked up today on third-quarter results that came in ahead of the consensus forecast. The Minneapolis-based implantable neuromodulation technology developer posted losses of $6.1 million, or 30¢ per share, on sales of $3.4 million for the three months ended Sept. 30, 2021, for a nearly doubled bottom-line slide deeper into the red […]
Medtech veteran Martha Shadan joins CVRx board of directors
CVRx today said that medtech veteran Martha Shadan has joined its board of directors. Shadan has more than 30 years of experience in the life sciences industry and has a long track record of success in commercializing medtech innovations in startups and large companies. She is currently the CEO of Miach Orthopedics. She has also […]
MedTech 100 roundup: Significant uptick for industry
The up-and-down nature of the medtech industry continues to carry through 2021, with a recent dip now followed by a rapid ascent. MassDevice‘s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished the week (June 11) at 109.63 points, producing a 2.5% rise from the 106.96-point mark set one […]
CVRx is going the IPO route
CVRx plans to hold an IPO to raise up to $75 million as it seeks to further commercialize its neuromodulation device to treat the heart. That’s according to a June 4 registration statement with the U.S. Securities and Exchange Commission that follows up on a registration confidentially filed with the SEC in April. The plan […]
CVRx secures reimbursement win from CMS
CVRx announced that it received the CMS inpatient new technology add-on payment (NTAP) for its Barostim Neo implantable device. Effective Oct. 1, 2020, and ranging over a three-year duration, Medicare is slated to provide an add-on payment for Barostim Neo worth up to 65% of the device cost (up to a maximum amount allowed of […]
Medical Alley companies raise $1B in Q3
The Medical Alley Association announced today that, through three quarters, its member companies raised more than a record-breaking $1 billion in capital for the first time. Last year, the association’s members raised more than $1 billion over the course of a full year, but this year, the 58 member companies took just three quarters to […]
CVRx CEO Yared on selling during a pandemic and improving diversity, equality inside and outside of medtech
In part 2 of an interview, we follow up with last week’s guest, CVRx CEO Nadim Yared, to catch up on how the medtech executive is managing during the pandemic. Yared also shares some far-reaching views on what the medtech industry needs to work toward to improve diversity in its workforce and provide equality for […]
